Searched for
PHARMACEUTICAL COMEBACK
5 mid-cap stocks from different sectors with an upside potential of 13 to 24% in one year, according to analystsWhen mid-caps were rising, every concern on valuation was treated as unnecessary caution. Investors who advised patience were told they wer...- India’s rising export champion faces a critical credibility testIndia's seafood exports are soaring, reaching record highs and aiming for $30 billion within five years. Despite overcoming US tariffs and ...
- Sensex falls over 300 points, Nifty below 23,350 amid persistent FII sellingIndian stock markets opened lower on Thursday, with Sensex and Nifty declining due to persistent FII selling and global headwinds. Geojit I...
- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Ahead of Market: 10 things that will decide D-Street action on MondayBulls staged a sharp rebound on Thursday, lifting Sensex and Nifty to a second straight gain despite high volatility. IT stocks led the rec...
- Why is the Dow Jones rising sharply today despite global tensions - Dow jumps 414 points as S&P 500 and Nasdaq gain big amid falling oil pricesDow Jones jumped 414 points today, leading a sharp US stock market rally despite global tensions. The Dow Jones surge today reflects easing...
- India’s industrial production hits two-year high with 6.7% growth in NovemberIndia's industrial output surged 6.7% year-on-year in November 2025, a significant rebound from October's slowdown. Manufacturing, particul...
- IT sector faces slower growth despite AI buzz; midcap firms better placed: Nitin RahejaIndia is not yet participating in the global AI rally. Consumption is expected to remain a key growth driver. Financials are poised for an ...
- Comeback kings! Reliance Power, Reliance Infra among 40 turnaround stories of FY25. Watchlist material?At least 40 companies rebounded from FY24 losses to FY25 profits, with nine stocks yielding over 100% returns. Reliance Power and Reliance ...
- Necessary pill for portfolio during volatility and Trump tariff wars: 8 pharma stocks with an upside potential of up to 48%Let’s accept the fact that we are likely to be dealing with volatility for the next four years. Both in the real world and in the global an...
- Business and valuation tailwinds to help in outperformance? 5 Indian pharma stocks with upside potential of up to 32%Just before the whole market was consumed by the PSU rally, one sector that came into the limelight after many years of underperformance wa...
- Must-reads from the week: 10 stocks with strong recos, how India can save $4 billion in oil imports and struggles of TCSA rundown of the five most important, popular and interesting stories on ET Prime this week.
- Mankind Pharma plans $1 billion IPO, hires bankersIn the proposed offer for sale, existing investors ChrysCapital will sell about 1% stake, Capital International will sell another 6% while ...
- Market Movers: Fear runs amok on D-Street as buyers go for hidingThe fear was palpable in the deep shade of red that painted trading screens and it was evident in the biggest spike in the India VIX index ...
- 34% returns in one year; ICICI Prudential Value Discovery Fund is back with a bangAfter a long rough phase of underperformance, ICICI Prudential Value Discovery Fund is back with a bang. The scheme has being criticised by...
- Merger and acquisition deals spike in 2nd half as firms strive to stay afloatDeal volumes are now down about 6% for the year to $3.5 trillion, according to data compiled by Bloomberg. Still, the fact that about two-t...
- Is the pharma rally here to stay? CLSA explains why stocks ralliedThe sector was underperforming for last three years amid pricing policy in US generics markets.
- Strides Arcolab Q2 net profit rises to Rs 19 croreConsolidated total income of the company rose to Rs 370 crore for the quarter under review. It was Rs 286.97 crore for the same period year...
- First half of FY'15 to observe better hiring sentiment: ReportHiring is likely to pick up in the first half of this fiscal, with healthcare, pharmaceutical etc.anticipated to add maximum jobs, accordin...
Load More
